Who won EIC Accelerator Open 2023? 141 companies funded
- 126funded projects
- €299.7MEU contribution
- 141companies, 140 SMEs
- 23countries
Grant topic: EIC Accelerator Open 2023
The European Commission funded 126 projects under the Horizon Europe topic HORIZON-EIC-2023-ACCELERATOROPEN-01, with €299.7M in total EU contribution. 141 private companies from 23 countries took part, and 140 of them are SMEs. Below is who they are, what they are building, and how much each received.
At a glance
- Funded projects: 126
- Total EU contribution: €299.7M
- Of which to companies: €299.7M (100%)
- Companies / of which SMEs: 141 / 140
- Average consortium size: 1.1 organisations
- Projects coordinated by a company: 126 of 126
- Top countries (company participations): the Netherlands (23), France (20), Germany (14), Sweden (11)
Companies that received funding
Paragate Medical Ltd
Nazareth, Israel · SME · project coordinator
Received €2.5M as a coordinator in FILBERT: An innovative implantable device and management platform to prevent chronic fluid congestion (2023-08 to 2025-07).
Elonroad AB
Lund, Sweden · SME · project coordinator
Received €2.5M as a coordinator in Elonroad: On-the-go charging system for heavy electric vehicles in ports and other closed loop applications (2023-08 to 2025-07).
Sentryx BV
Austerlitz, the Netherlands · SME · project coordinator
Received €2.5M as a coordinator in OPERAS: Opioid-free Pain relief for Enhanced Recovery After Spine fixation surgery (2023-04 to 2026-03).
SAMPLIX ApS
Birkerod, Denmark · SME · project coordinator
Received €2.5M as a coordinator in Cellularity: The critical shift to single-cell formats in functional analyses of living cells (2023-08 to 2025-07).
Excess Engineering AS
Sandnes, Norway · SME · project coordinator
Received €2.5M as a coordinator in Electric Actuator: Electrification of heavy machinery (2023-08 to 2025-05).
Plenesys
Valbonne, France · SME · project coordinator
Received €2.5M as a coordinator in hyplasma: A clean and cost competitive hydrogen production solution near the end user thanks to an innovative plasma methane pyrolysis technology (2023-12 to 2025-11).
Diogenx SAS
Marseille, France · SME · project coordinator
Received €2.5M as a coordinator in DiogenX: Beta-cell recovery to counter diabetes (2023-10 to 2025-09).
Molecular Attraction AB
Nacka, Sweden · SME · project coordinator
Received €2.5M as a coordinator in SemioMVC: Mosquito-specific phagostimulants and pheromones for environment-friendly mosquito vector control (2023-12 to 2026-05).
Butterfly Medical Ltd
Yokneam, Israel · SME · project coordinator
Received €2.5M as a coordinator in MPRD: Innovative, minimally invasive Medical Prostatic Retraction Device for the treatment of Benign Prostatic Hyperplasia (BPH) Patients in the office settings. (2023-09 to 2025-08).
Escala Medical Ltd
Misgrav, Israel · SME · project coordinator
Received €2.5M as a coordinator in apyx: The first non-surgical repair for Pelvic Organ Prolapse (2023-10 to 2025-09).
Cellbox Solutions
Koln, Germany · SME · project coordinator
Received €2.5M as a coordinator in CELLBOX: Innovative transport of “in culture” cell-based materials ensuring product safety, quality and function (2023-10 to 2025-09).
Stentit BV
Eindhoven, the Netherlands · SME · project coordinator
Received €2.5M as a coordinator in EX-STENT: THE NEXT STENT GENERATION: A FIRST-IN-CLASS REGENERATIVE NANOFIBER STENT TO RECONSTRUCT ARTERIES FROM THE INSIDE OUT (2023-09 to 2025-11).
Also funded: Neureality Ltd (IL), Bioprotect Ltd (IL), Neogap Therapeutics AB (SE), Picterus AS (NO), Giskard Ai (FR), Vortex.io (FR), Nemysis Limited (IE), Inbiome BV (NL), Orange Quantum Systems Operational BV (NL), Beit sp. z o.o. (PL), Tamponeni Inovatsii OOD (BG), Medicsensors SL (ES), Gaft BV (NL), Ocean Grazer BV (NL), MIMARK Diagnostics SL (ES), Kvantify ApS (DK), Celtic Biotech Ltd (IE), Thirona BV (NL), Angiolutions GmbH (DE), Luminate Medical Limited (IE), Zigrid AB (SE), Hooke Bio Ltd (IE), Magneto BV (NL), Chaincraft BV (NL), Uromems (FR), Hbox Therapies GmbH (DE), Raiku Packaging OÜ (EE), Hephaistos-Pharma (FR), Ervimmune (FR), Ever Dye (FR), Tafalgie Therapeutics (FR), Peptinov (FR), Resother Pharma AS (DK), Targtex SA (PT), MOI Composites SRL (IT), Betaglue Therapeutics SpA (IT), Gedea Biotech AB (SE), Salvia Bioelectronics BV (NL), D-Crbn (BE), Novelrad Ltd (IL), and 89 more.
The funded projects
The ten largest of 126 projects by EU contribution:
FILBERT: An innovative implantable device and management platform to prevent chronic fluid congestion
€2.5M EU contribution · 1 partner · 2023-08 to 2025-07 · coordinated by Paragate Medical Ltd (IL)
Pathologic fluid overload is a main clinical complication of congestive heart failure (CHF). CHF is a severe chronic disease affecting ~28 M people worldwide. Around 8 M of CHF patients are resistant to oral medications and undergo frequent hospitalizations to remove extra fluids with aggressive acute treatments, all carrying severe complications. None of these treatments can prevent fluid accumulation.
Elonroad: On-the-go charging system for heavy electric vehicles in ports and other closed loop applications
€2.5M EU contribution · 1 partner · 2023-08 to 2025-07 · coordinated by Elonroad AB (SE)
Ports account for ~30% of CO2 emissions in the shipping industry, mostly caused by diesel-powered machinery. While regulators are pushing for industry electrification, charging infrastructure is lagging and creates major barriers for electrification. Elonroad’s electric road system can charge any heavy vehicle (in motion or parked). It enables much smaller batteries that allow OEMs to reduce vehicle costs.
OPERAS: Opioid-free Pain relief for Enhanced Recovery After Spine fixation surgery
€2.5M EU contribution · 1 partner · 2023-04 to 2026-03 · coordinated by Sentryx BV (NL)
There is a troubling lack of effective pain treatments after major surgery. Especially after musculoskeletal procedures, patients experience debilitating pain now treated with opioids. Opioids provide insufficient pain relief, have many toxic side-effects, and are highly addictive.
Cellularity: The critical shift to single-cell formats in functional analyses of living cells
€2.5M EU contribution · 1 partner · 2023-08 to 2025-07 · coordinated by SAMPLIX ApS (DK)
The incredible potential of cell and immune therapy (CIT) is limited by technical challenges related to the standard analysis of immune cells in bulk, which neglects their heterogeneity. Single-cell functional resolution is essential to understand the full potential of immune cells.
Electric Actuator: Electrification of heavy machinery
€2.5M EU contribution · 1 partner · 2023-08 to 2025-05 · coordinated by Excess Engineering AS (NO)
We have invented and developed a specific solution for one of the key components found within most of the worlds excavators, cranes, construction machinery. Excess Engineering have patented and tested a new revolutionary electric actuator that can replace all type of hydraulic systems. Electric systems available in the market today has never been able to replace hydraulic systems in construction machines.
hyplasma: A clean and cost competitive hydrogen production solution near the end user thanks to an innovative plasma methane pyrolysis technology
€2.5M EU contribution · 1 partner · 2023-12 to 2025-11 · coordinated by Plenesys (FR)
HyPlasma aims at bringing to the market an integrated solution for the production of affordable clean Hydrogen. The process is based on methane pyrolysis, which transforms natural gas (or biomethane) into clean Hydrogen on one hand, and solid carbon on the other hand: it therefore avoids CO2 emissions.
DiogenX: Beta-cell recovery to counter diabetes
€2.5M EU contribution · 1 partner · 2023-10 to 2025-09 · coordinated by Diogenx SAS (FR)
Globally 8,75M people with T1D rely only on insulin administration to manage the symptoms of their disease. The treatment is complex since it requires injecting insulin (2-4 times/day) and adhering to a restrictive lifestyle (e.g., following a strict diet) reducing patient QoL.
SemioMVC: Mosquito-specific phagostimulants and pheromones for environment-friendly mosquito vector control
€2.5M EU contribution · 1 partner · 2023-12 to 2026-05 · coordinated by Molecular Attraction AB (SE)
Each year, chemicals worth €8bn are used for Mosquito Vector Control (MVC). Still, mosquito-borne diseases constitute a major socio-economic burden. As insecticides start losing efficacy and toxic chemicals are being banned from use (in the west in particular), we are becoming increasingly defenceless.
MPRD: Innovative, minimally invasive Medical Prostatic Retraction Device for the treatment of Benign Prostatic Hyperplasia (BPH) Patients in the office settings.
€2.5M EU contribution · 1 partner · 2023-09 to 2025-08 · coordinated by Butterfly Medical Ltd (IL)
Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment. Butterflys innovative device transfers the procedure from the operating room to the clinic, with the device being placed in 6 to 8 minutes, in doctors office, under local anaesthesia.
apyx: The first non-surgical repair for Pelvic Organ Prolapse
€2.5M EU contribution · 1 partner · 2023-10 to 2025-09 · coordinated by Escala Medical Ltd (IL)
Pelvic Organ Prolapse (POP) affects nearly 50% of women over 40 years old globally. 89% of the cases seek treatment for symptomatic early stage prolapse. Despite the high prevalence and the progression of POP over time, patients currently cannot be offered a repair solution until the condition worsens enough for surgical intervention.
What the winning consortia had in common
- Consortia averaged 1.1 organisations, and companies held 141 of 143 seats (99%).
- 99% of company seats went to SMEs, so smaller firms clearly had room in these consortia.
- 126 of 126 projects were coordinated by a company; the rest were led by universities, research organisations or public bodies.
See the original call on Grantalist.
Source: CORDIS Horizon Europe open data, © European Union, reused under CC BY 4.0. Figures are the EU contribution recorded at grant signature; data as of 2026-08-28.